Razagilin Glenmark Pharmaceuticals 1 mg tablete Slowenien - Slowenisch - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

razagilin glenmark pharmaceuticals 1 mg tablete

glenmark pharmaceuticals s.r.o. - razagilin - tableta - razagilin 1 mg / 1 tableta - razagilin

Zavicefta Europäische Union - Slowenisch - EMA (European Medicines Agency)

zavicefta

pfizer ireland pharmaceuticals - avibactam sodium, ceftazidime pentahydrate - pneumonia, bacterial; soft tissue infections; pneumonia; urinary tract infections; gram-negative bacterial infections - antibacterials za sistemsko uporabo, - zavicefta is indicated in adults and paediatric patients aged 3 months and older for the treatment of the following infections:complicated intra-abdominal infection (ciai)complicated urinary tract infection (cuti), including pyelonephritishospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap)treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. zavicefta is also indicated for the treatment of infections due to aerobic gram-negative organisms in adults and paediatric patients aged 3 months and older with limited treatment options. upoštevati je treba uradne smernice za ustrezno uporabo protibakterijsko agenti.

Deferasirox Mylan Europäische Union - Slowenisch - EMA (European Medicines Agency)

deferasirox mylan

mylan pharmaceuticals limited - deferasiroks - iron overload; beta-thalassemia - kelator železa - deferasirox mylan je označena forthe zdravljenje kronične železa preobremenitve zaradi pogoste transfuzije krvi (≥7 ml/kg/mesec pakirani rdečih krvničk) pri bolnikih z beta talasemija major, starih 6 let in olderthe zdravljenje kronične železa preobremenitve zaradi transfuzije krvi, če deferoxamine zdravljenje je kontraindicirano ali neustrezni v naslednjih bolnik skupine:v pediatričnih bolnikih z beta talasemija major preobremenitve z železom zaradi pogoste transfuzije krvi (≥7 ml/kg/mesec pakirani rdečih krvnih celic), starih od 2 do 5 let,pri odraslih in pediatričnih bolnikih z beta talasemija major preobremenitve z železom zaradi redke transfuzije krvi (.

Cosentyx Europäische Union - Slowenisch - EMA (European Medicines Agency)

cosentyx

novartis europharm limited - secukinumab - arthritis, psoriatic; psoriasis; spondylitis, ankylosing - imunosupresivi - plaque psoriasiscosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy. hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy. psoriatični arthritiscosentyx, samostojno ali v kombinaciji z metotreksatom (mtx), je primerna za zdravljenje aktivnega psoriatičnega artritisa pri odraslih bolnikih, kadar je odgovor na prejšnje bolezni spreminjanje anti revmatičnih drog (dmard) terapija je bila neustrezna. aksialni spondyloarthritis (axspa)ankilozirajoči spondilitis (kot, radiografski osno spondyloarthritis)cosentyx je primerna za zdravljenje aktivnega ankilozirajoči spondilitis pri odraslih, ki so se odzvali neustrezno konvencionalne terapije. non-radiographic axial spondyloarthritis (nr-axspa)cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (nsaids). juvenile idiopathic arthritis (jia)enthesitis-related arthritis (era)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. juvenile psoriatic arthritis (jpsa)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.

DepoCyte Europäische Union - Slowenisch - EMA (European Medicines Agency)

depocyte

pacira limited - citarabin - meningealne neoplazme - antineoplastična sredstva - intratekalno zdravljenje limfomatoznega meningitisa. pri večini bolnikov bo takšno zdravljenje del simptomatske paliacije bolezni.

Eksemestan Intas 25 mg filmsko obložene tablete Slowenien - Slowenisch - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

eksemestan intas 25 mg filmsko obložene tablete

intas pharmaceuticals limited - eksemestan - filmsko obložena tableta - eksemestan 25 mg / 1 tableta - eksemestan

Eksemestan Intas 25 mg filmsko obložene tablete Slowenien - Slowenisch - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

eksemestan intas 25 mg filmsko obložene tablete

intas pharmaceuticals limited - eksemestan - filmsko obložena tableta - eksemestan 25 mg / 1 tableta - eksemestan

Eksemestan Intas 25 mg filmsko obložene tablete Slowenien - Slowenisch - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

eksemestan intas 25 mg filmsko obložene tablete

intas pharmaceuticals limited - eksemestan - filmsko obložena tableta - eksemestan 25 mg / 1 tableta - eksemestan

Eksemestan Intas 25 mg filmsko obložene tablete Slowenien - Slowenisch - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

eksemestan intas 25 mg filmsko obložene tablete

intas pharmaceuticals limited - eksemestan - filmsko obložena tableta - eksemestan 25 mg / 1 tableta - eksemestan

Eksemestan Intas 25 mg filmsko obložene tablete Slowenien - Slowenisch - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

eksemestan intas 25 mg filmsko obložene tablete

intas pharmaceuticals limited - eksemestan - filmsko obložena tableta - eksemestan 25 mg / 1 tableta - eksemestan